Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)

Funding Agency:
National Institutes of Health

The purpose of this notice of this funding opportunity (NOFO) is to support translational research across epidemiology, addiction services, and prevention to, ultimately, reduce the burden of substance use on public health. This NOFO encourages research that facilitates rapid translation from one discipline to another (e.g., epidemiology to prevention); supports community/stakeholder engagement in substance use treatment and prevention clinical trials; or reduces the research to practice gap through the rapid transition from pilot study to clinical trial, or effectiveness to implementation study.  The goal is to support translational research improving our ability to  1) identify and characterize malleable individual, familial, behavioral, developmental, and socio-cultural/environmental factors (within the population or precise subgroups) with the potential for multi-directional transfer of knowledge;  2) prevent initiation of substance use or progression to misuse or use disorder; and  3) maximize the efficient delivery of high-quality, personalized addiction treatment and related services to ultimately inform and facilitate real world responses designed to reduce the burden of substance use, misuse and/or addiction on the health of the population. This NOFO invites projects for which preliminary feasibility or pilot data are not available. 

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.


  • Letter of Intent Due Date(s): One month prior to application due date.

  • Application Due Dates: Feb 14, 2024; Aug 14, 2024; Nov 13, 2024; Feb 14, 2025; Aug 14, 2025; Nov 14, 2025; Feb 13, 2026; Aug 14, 2026; Nov 13, 2026

  • AIDS Due Dates: Mar 15, 2024; Aug 14, 2024; Dec 13, 2024; Mar 17, 2025; Aug 14, 2025; Dec 15, 2025; Mar 16, 2026; Aug 14, 2026; Dec 14, 2026

PAR-24-062 Expiration Date November 14, 2026

Agency Website

Amount Description

Application budgets must reflect the actual needs of the proposed project. The R61 phase is limited to a budget of no more than $350,000 in direct costs per year and the R33 phase is limited to a budget of no more than $750,000 in direct costs per year.

Funding Type





Medical - Translational

External Deadline

August 14, 2024